MCID: HMN010
MIFTS: 60

Hemangioma

Categories: Blood diseases, Cancer diseases, Genetic diseases, Neuronal diseases

Aliases & Classifications for Hemangioma

MalaCards integrated aliases for Hemangioma:

Name: Hemangioma 38 12 76 29 55 6 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:255
ICD10 33 D18.0 D18.00
ICD9CM 35 228.0 228.00
MeSH 44 D006391
NCIt 50 C3085
SNOMED-CT 68 2099007 93474003
UMLS 73 C0018916

Summaries for Hemangioma

Disease Ontology : 12 A cell type benign neoplasm that has material basis in endothelial cells that line blood vessels and is characterised by increased number of normal or abnormal vessels filled with blood.

MalaCards based summary : Hemangioma is related to hemangioma, capillary infantile and cavernous hemangioma. An important gene associated with Hemangioma is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Akt Signaling and PAK Pathway. The drugs Sufentanil and Parecoxib have been mentioned in the context of this disorder. Affiliated tissues include Heart, liver and endothelial, and related phenotypes are Decreased sensitivity to paclitaxel and cardiovascular system

Wikipedia : 76 Hemangioma is a benign tumor derived from blood vessel cell types, most commonly infantile hemangioma, a... more...

Related Diseases for Hemangioma

Diseases in the Hemangioma family:

Malignant Hemangioma Acquired Hemangioma
Familial Hemangioma

Diseases related to Hemangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 593)
# Related Disease Score Top Affiliating Genes
1 hemangioma, capillary infantile 34.2 ANTXR1 FLT4 KDR
2 cavernous hemangioma 33.9 CCM2 KDR KRIT1 NKX2-1
3 capillary hemangioma 33.9 ANTXR1 KDR SLC2A1 TEK VEGFA VHL
4 glomeruloid hemangioma 33.6 CD34 VEGFA
5 hemangioma of lung 33.4 NKX2-1 SFTPB
6 skin hemangioma 33.4 KDR PROX1 SLC2A1 VEGFA
7 intramuscular hemangioma 33.3 CD34 SLC2A1 TEK
8 acquired hemangioma 33.3 PDPN PROX1
9 hemangioma of liver 33.3 CD34 KRIT1 VHL
10 malignant hemangioma 33.3 CD34 FLT4 KDR
11 cerebral cavernous malformations 33.2 CCM2 KDR KRIT1 PTEN
12 hobnail hemangioma 33.2 CD34 FLT4 PDPN
13 pyogenic granuloma 33.1 ACTC1 ANGPT2 TEK VEGFA
14 hemangioendothelioma 32.7 FLT4 KDR
15 klippel-trenaunay-weber syndrome 32.3 CCM2 FLT4 KRIT1
16 angiosarcoma 32.1 FLT4 KDR KRAS PROX1 TEK VEGFA
17 malignant epithelioid hemangioendothelioma 31.6 CD34 FLT4 KDR
18 adenocarcinoma 30.3 KDR KRAS PTEN VEGFA
19 renal cell carcinoma, nonpapillary 30.2 FGF2 FLT4 KDR NKX2-1 VEGFA VHL
20 intravascular papillary endothelial hyperplasia 30.2 ACTC1 VEGFA
21 lymphatic malformations 30.2 FLT4 PROX1
22 angiokeratoma circumscriptum 30.1 KDR SLC2A1 VEGFA
23 hemangioblastoma 30.1 SLC2A1 VEGFA VHL
24 lymphangioma 30.0 ACTC1 FLT4 KDR PDPN PROX1 VEGFA
25 human venous malformation 30.0 CCM2 KRIT1 TEK
26 kaposiform hemangioendothelioma 29.9 CD34 FLT4 KDR PROX1
27 angiodysplasia 29.9 ANGPT2 FGF2 VEGFA
28 exudative vitreoretinopathy 1 29.9 ANGPT2 KDR TEK VEGFA
29 hemifacial spasm 29.8 FLT4 VEGFA
30 glomangioma 29.6 ACTC1 TEK
31 clear cell renal cell carcinoma 29.6 KDR PTEN SLC2A1 VEGFA VHL
32 thyroid cancer 29.6 KDR KRAS NKX2-1 PTEN SLC2A1 VEGFA
33 myeloma, multiple 29.6 CD34 FGF2 KRAS VEGFA
34 endometrial adenocarcinoma 29.5 FGF2 KRAS PTEN VEGFA
35 kidney cancer 29.5 KDR VEGFA VHL
36 gastrointestinal stromal tumor 29.4 ACTC1 CD34 KRAS PTEN VEGFA
37 meningioma, familial 29.3 CD34 PTEN VEGFA
38 adenoid cystic carcinoma 29.3 ACTC1 KRAS PDPN PTEN VEGFA
39 glioma 29.1 FGF2 KDR PTEN VEGFA
40 hemangioma-thrombocytopenia syndrome 12.4
41 histiocytoid hemangioma 12.4
42 non-involuting congenital hemangioma 12.4
43 sclerosing hemangioma 12.3
44 breast epithelioid hemangioma 12.2
45 bone epithelioid hemangioma 12.2
46 breast capillary hemangioma 12.1
47 pulmonary sclerosing hemangioma 12.1
48 hemangioma of spleen 12.1
49 spindle cell hemangioma 12.1
50 skin epithelioid hemangioma 12.1

Graphical network of the top 20 diseases related to Hemangioma:



Diseases related to Hemangioma

Symptoms & Phenotypes for Hemangioma

GenomeRNAi Phenotypes related to Hemangioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.62 PTEN VHL

MGI Mouse Phenotypes related to Hemangioma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.49 ACTC1 ANGPT2 ANTXR1 CCM2 FGF2 FLT4
2 homeostasis/metabolism MP:0005376 10.45 ACTC1 ANGPT2 CCM2 CD34 FGF2 FLT4
3 cellular MP:0005384 10.43 ACTC1 ANGPT2 ANTXR1 CCM2 CD34 FGF2
4 growth/size/body region MP:0005378 10.42 ACTC1 ANTXR1 CCM2 FLT4 KDR KRAS
5 mortality/aging MP:0010768 10.41 ACTC1 ANGPT2 ANTXR1 CCM2 FGF2 FLT4
6 behavior/neurological MP:0005386 10.34 CCM2 FGF2 KDR KRAS NKX2-1 PDPN
7 immune system MP:0005387 10.29 ANGPT2 ANTXR1 CCM2 CD34 FLT4 KDR
8 hematopoietic system MP:0005397 10.28 CCM2 CD34 FGF2 KDR KRAS PDPN
9 embryo MP:0005380 10.26 CCM2 FLT4 KDR KRAS KRIT1 PTEN
10 muscle MP:0005369 10.25 ACTC1 CCM2 FGF2 FLT4 KDR KRAS
11 integument MP:0010771 10.24 ANGPT2 CCM2 CD34 FLT4 KDR KRAS
12 digestive/alimentary MP:0005381 10.22 ANGPT2 FLT4 KRAS NKX2-1 PDPN PROX1
13 craniofacial MP:0005382 10.12 ANTXR1 CCM2 KDR KRAS KRIT1 VEGFA
14 nervous system MP:0003631 10.11 CCM2 FGF2 KDR KRAS KRIT1 NKX2-1
15 neoplasm MP:0002006 10.06 ANTXR1 CD34 FGF2 KRAS KRIT1 NKX2-1
16 liver/biliary system MP:0005370 10.02 FLT4 KDR KRAS PROX1 PTEN VEGFA
17 normal MP:0002873 10 ACTC1 CCM2 FLT4 KDR KRAS NKX2-1
18 no phenotypic analysis MP:0003012 9.87 ANTXR1 FLT4 KDR KRAS NKX2-1 SLC2A1
19 respiratory system MP:0005388 9.81 ANGPT2 KDR KRAS NKX2-1 PDPN PROX1
20 skeleton MP:0005390 9.61 ANTXR1 FGF2 KDR KRAS NKX2-1 PDPN
21 vision/eye MP:0005391 9.36 ANGPT2 CCM2 FGF2 KDR KRAS KRIT1

Drugs & Therapeutics for Hemangioma

Drugs for Hemangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 211)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
2
Parecoxib Approved Phase 4 198470-84-7
3
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
4
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 525-66-6 4946
5
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
7
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
8
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
9
Ethiodized oil Approved, Investigational Phase 4,Phase 1 8008-53-5
10
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2 2920-86-7
11 Central Nervous System Depressants Phase 4,Not Applicable
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Analgesics, Opioid Phase 4
14 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Cyclooxygenase Inhibitors Phase 4
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4
17 Cyclooxygenase 2 Inhibitors Phase 4
18 Anesthetics Phase 4,Not Applicable
19 Anesthetics, Intravenous Phase 4
20 Narcotics Phase 4
21 Adjuvants, Anesthesia Phase 4
22 Analgesics Phase 4,Not Applicable
23 Anesthetics, General Phase 4
24 Antirheumatic Agents Phase 4
25 Analgesics, Non-Narcotic Phase 4,Not Applicable
26 Hypnotics and Sedatives Phase 4,Not Applicable
27 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Adrenergic alpha-Agonists Phase 4,Not Applicable
29 Adrenergic alpha-2 Receptor Agonists Phase 4,Not Applicable
30 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Adrenergic Agonists Phase 4,Not Applicable
32 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Prednisolone acetate Phase 4,Phase 3,Phase 2
38 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
39 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
41 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
42 Antiemetics Phase 4,Phase 3,Phase 2
43 Methylprednisolone acetate Phase 4,Phase 3,Phase 2
44 Neuroprotective Agents Phase 4,Phase 3,Phase 2
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
46 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
47 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
49
Timolol Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 26839-75-8 33624 5478
50
Atenolol Approved Phase 3 29122-68-7 2249

Interventional clinical trials:

(show top 50) (show all 221)
# Name Status NCT ID Phase Drugs
1 Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy Unknown status NCT02204878 Phase 4 Parecoxib Sodium
2 Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery Unknown status NCT02552459 Phase 4 Sufentanil;dexmedetomidine 1;dexmedetomidine 2;dexmedetomidine 3
3 Visceral Artery Aneurysm Embolization by the Penumbra Ruby™ Coil System Unknown status NCT02079818 Phase 4
4 The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma Completed NCT01908972 Phase 4 Prednisolone;Propranolol
5 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
6 Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain Recruiting NCT03181984 Phase 4 Hemoporfin
7 A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain Recruiting NCT03125057 Phase 4 Hemoporfin PDT
8 Topical Timolol for Superficial Infantile Hemangioma Unknown status NCT01685398 Phase 3 0.5% timolol maleate eye drop;Normal saline
9 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
10 Functional Magnetic Resonance Imagine(fMRI)Navigation in Intracranial Arteriovenous Malformation Surgery Unknown status NCT01758211 Phase 3
11 Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy Completed NCT01056341 Phase 2, Phase 3 Propranolol;Placebo
12 Pulse Steroids Versus Oral Steroids in Problematic Hemangiomas of Infancy Completed NCT00312520 Phase 3 prednisolone;methylprednisolone
13 Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma Completed NCT02342275 Phase 3 Propranolol;Atenolol
14 Evaluation of Vertebroplasty Associated With Radiotherapy for Spine Metastases (EVAR) Completed NCT00267033 Phase 3
15 A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation Completed NCT01677624 Phase 3
16 A Randomized Trial of Unruptured Brain AVMs Completed NCT00389181 Phase 3
17 SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization Completed NCT00829413 Phase 3 SonoVue®
18 Nadolol Versus Propranolol in Children With Infantile Hemangiomas Recruiting NCT02505971 Phase 3 Nadolol;Propranolol
19 Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas Recruiting NCT03237637 Phase 3 oral propranolol;oral atenolol
20 CyberKnife Based Hypofractionated Radiotherapy for Vertebral Hemangiomas Recruiting NCT02332408 Phase 3
21 Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome Recruiting NCT03047980 Phase 2, Phase 3 Sirolimus
22 MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients Not yet recruiting NCT02962947 Phase 2, Phase 3 Propranolol;Placebo
23 Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction Not yet recruiting NCT03518398 Phase 3
24 Propranolol in Capillary Hemangiomas Terminated NCT00744185 Phase 2, Phase 3 propranolol treatment;placebo treatment
25 Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma Terminated NCT01743885 Phase 3 Acebutolol;Propanolol
26 Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma Unknown status NCT03033524 Phase 2 TTAC-0001
27 Topical Timolol Gel for the Treatment of Infantile Hemangiomas Completed NCT02145884 Phase 2 timolol maleate 0.5% gel
28 Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo Completed NCT01512173 Phase 2 propranolol gel;Placebo
29 Nadolol for Proliferating Infantile Hemangiomas Completed NCT01010308 Phase 2 Nadolol
30 A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy Completed NCT00601016 Phase 2 Imiquimod 5% cream
31 Topical Timolol for Infantile Hemangioma in Early Proliferative Phase Completed NCT02731287 Phase 2 Timolol;Placebo
32 Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma Completed NCT01072045 Phase 2 Propranolol;Prednisone
33 Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO) Completed NCT02484716 Phase 2 Timolol nasal spray;Placebo nasal spray
34 Treatment of Resistant Port-wine Stains With Bosentan and Pulsed Dye Laser: a Pilot Study Completed NCT02317679 Phase 2 Bosentan
35 Measurement Skin Temperature During Pulsed Laser Exposure Completed NCT00540917 Phase 2
36 Study Comparing Onyx and TRUFILL in Brain Arteriovenous Malformations (AVMs) Completed NCT00857662 Phase 2
37 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
38 Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 Completed NCT00052013 Phase 2 PTK787/ZK 222584
39 Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding Completed NCT00389935 Phase 2 Thalidomide
40 Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome Completed NCT02080624 Phase 2 Drug: Topical Rapamycin
41 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
42 Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) Recruiting NCT02913612 Phase 2 0.25% Timolol Maleate Gel Forming Solution;0.5% Timolol Maleate Gel Forming Solution
43 Efficacy Evaluation of Propranolol Treatment of Hepatic Hemangioma Recruiting NCT03633747 Phase 1, Phase 2 Propranolol Hydrochloride
44 Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial Recruiting NCT02603328 Phase 1, Phase 2 Atorvastatin
45 A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors Recruiting NCT02110069 Phase 2 Vincristine;Sirolimus
46 Treat_CCM: Propranolol in Cerebral Cavernous Malformation Recruiting NCT03589014 Phase 2 Propranolol
47 Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation Recruiting NCT03474614 Phase 2 Propranolol
48 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Recruiting NCT03302858 Phase 2
49 Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations Recruiting NCT02042326 Phase 2 Sirolimus
50 Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations Recruiting NCT03691870 Phase 2

Search NIH Clinical Center for Hemangioma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hemangioma

Genetic Tests for Hemangioma

Genetic tests related to Hemangioma:

# Genetic test Affiliating Genes
1 Hemangioma 29

Anatomical Context for Hemangioma

MalaCards organs/tissues related to Hemangioma:

41
Liver, Endothelial, Lung, Bone, Skin, Heart, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Hemangioma:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Cardinal Veins Venous Endothelial Cells Affected by disease

Publications for Hemangioma

Articles related to Hemangioma:

(show top 50) (show all 3683)
# Title Authors Year
1
Characterization of long-term outcomes for pediatric patients with epithelioid hemangioma. ( 30207085 )
2019
2
Sudden spinal hemorrhage in a pediatric case with total body irradiation-induced cavernous hemangioma. ( 29797651 )
2018
3
Giant Colonic Cavernous Hemangioma Causing Hematochezia inA a 14-Year-Old Boy. ( 29806995 )
2018
4
Vulvar Hemangioma: Case Report. ( 29980161 )
2018
5
Dural Penetration of Cavernous Hemangioma on Skull: Uncommon Clinical Presentation. ( 29109062 )
2018
6
Lobular capillary hemangioma of the mandible: A case report. ( 29704808 )
2018
7
Sinusoidal hemangioma and intravascular papillary endothelial hyperplasia: Interrelated processes that share a histogenetic piecemeal angiogenic mechanism. ( 29486986 )
2018
8
Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment. ( 29952019 )
2018
9
Analysis of the characteristics of optical coherence tomography angiography for retinal cavernous hemangioma: A case report. ( 29443780 )
2018
10
Cavernous hemangioma of the interatrial septum. ( 29629515 )
2018
11
Gastric fundus splenosis with hemangioma masquerading as a gastrointestinal stromal tumor in a patient with schistosomiasis and cirrhosis who underwent splenectomy: A case report and literature review. ( 29979450 )
2018
12
Role of thrombospondin-1 and nuclear factor-kappa B signaling pathways in anti-angiogenesis of infantile hemangioma. ( 29927834 )
2018
13
An unusual lesion on the nose: microvenular hemangioma. ( 29445567 )
2018
14
<sup>18</sup>F-FDG PET/CT characteristics of pulmonary sclerosing hemangioma vs. pulmonary hamartoma. ( 29930720 )
2018
15
Tocolysis with the I^<sub>2</sub>-sympathomimetic fenoterol does not increase the occurrence of infantile hemangioma in preterm and term infants. ( 29938346 )
2018
16
Transarterial Bleomycin-Lipiodol Embolization (B/LE) for Symptomatic Giant Hepatic Hemangioma. ( 29922860 )
2018
17
Ultrasound findings in rapidly involuting congenital hemangioma (RICH) - beware of venous ectasia and venous lakes. ( 29362838 )
2018
18
Optical Coherence Tomography Microangiography Imaging of Circumscribed Choroidal Hemangioma. ( 29443364 )
2018
19
Optic Nerve Meningioma Mimicking Cavernous Hemangioma. ( 29191527 )
2018
20
Multimodal Imaging of Optic Nerve Head Capillary Hemangioma. ( 29864074 )
2018
21
Capillary hemangioma associated with dermal atrophy masquerading as a deep fungal infection. ( 29634891 )
2018
22
Cervical corpectomy for resection of ventral intramedullary capillary hemangioma with circumferential involvement of the anterior spinal artery: case report. ( 29726799 )
2018
23
Letter to the Editor Regarding &amp;quot;Optic Nerve Meningioma Mimicking Cavernous Hemangioma&amp;quot;. ( 29499604 )
2018
24
Masson's Hemangioma of the Cheek: A Case Report. ( 29977863 )
2018
25
Subcutaneous Lobular Capillary Hemangioma Presenting as a Facial Mass. ( 29854524 )
2018
26
A new surgical technique for excision of orbital cavernous hemangioma: a 15-year experience. ( 29442536 )
2018
27
Venous outlet syndrome caused by capillary hemangioma of the subclavian vein. ( 29444598 )
2018
28
The value of clinical and ultrasound features for the diagnosis of infantile hepatic hemangioma: Comparison with contrast-enhanced CT/MRI. ( 29957348 )
2018
29
Linear verrucous hemangioma-a rare case and dermoscopic clues to diagnosis. ( 29445574 )
2018
30
Solitary Retinal Capillary Hemangioma with Nonlipid Exudative Retinal Detachment. ( 29389404 )
2018
31
Fever of unknown origin: a rare presentation of giant hepatic hemangioma. ( 29942486 )
2018
32
Endoscopic management of Atypical sellar cavernous hemangioma: A case report and review of the literature. ( 29248833 )
2018
33
Venous Malformation (Cavernous Hemangioma) of the Supraorbital Nerve. ( 29682072 )
2018
34
Cavernous Hemangioma Between the Elastomer and Fibrous Capsule of a Breast Implant. ( 29872905 )
2018
35
Moyamoya Disease Associated with Tuberculum Sellae Meningioma and Cavernous Sinus Hemangioma. ( 28958924 )
2018
36
Glomeruloid hemangioma associated with TAFRO syndrome. ( 29702119 )
2018
37
Utility of contrast-enhanced ultrasonography with perflubutane in evaluating indications for diagnostic percutaneous tumor biopsy in a case of hepatic sclerosed hemangioma. ( 29931440 )
2018
38
Rare case of bleeding nipple hemangioma in a lactating mother. ( 29977507 )
2018
39
Massive hemorrhage: A rare complication of rapidly involuting congenital hemangioma. ( 29572940 )
2018
40
Pulmonary hemangioma mimicking bronchiectasis: A case report. ( 29924044 )
2018
41
Treatment of retinal capillary hemangioma using 810 nm infrared laser. ( 29765174 )
2018
42
Hemangioma of the Hard Palate in an Elderly Patient as a Life-Threatening Surgical Emergency. ( 29438210 )
2018
43
RETINAL CAVERNOUS HEMANGIOMA WITH INTRALESIONAL PHLEBOLITHS. ( 29505489 )
2018
44
Congenital Hemangioma: A Case Report of a Finding Every Physician Should Know. ( 29922526 )
2018
45
A Giant Cardiac Cavernous Hemangioma Involving the Left Atrial Roof in an Elderly Woman. ( 29459567 )
2018
46
Curcumin induces apoptosis and inhibits proliferation in infantile hemangioma endothelial cells via downregulation of MCL-1 and HIF-1I+. ( 29443732 )
2018
47
I^-Adrenoceptor Blockade for Infantile Hemangioma Therapy: Do I^3-Adrenoceptors Play a Role? ( 29936502 )
2018
48
Effects of oral propranolol for circumscribed choroidal hemangioma. ( 29924188 )
2018
49
Multidisciplinary management of an intra-sellar cavernous hemangioma: Case report and review of the literature. ( 29622503 )
2018
50
Long-Term Therapeutic Outcomes of Photodynamic Therapy-Based or Photocoagulation-Based Treatments on Retinal Capillary Hemangioma. ( 29068750 )
2018

Variations for Hemangioma

ClinVar genetic disease variations for Hemangioma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.675T> G (p.Tyr225Ter) single nucleotide variant Pathogenic rs1057520900 GRCh37 Chromosome 10, 89717650: 89717650
2 PTEN NM_000314.6(PTEN): c.675T> G (p.Tyr225Ter) single nucleotide variant Pathogenic rs1057520900 GRCh38 Chromosome 10, 87957893: 87957893
3 RPL5 NM_000969.3(RPL5): c.74-1G> C single nucleotide variant Pathogenic GRCh37 Chromosome 1, 93299101: 93299101
4 RPL5 NM_000969.3(RPL5): c.74-1G> C single nucleotide variant Pathogenic GRCh38 Chromosome 1, 92833544: 92833544
5 PKD1 NM_001009944.2(PKD1): c.359T> C (p.Ile120Thr) single nucleotide variant Likely pathogenic GRCh38 Chromosome 16, 2119114: 2119114
6 PKD1 NM_001009944.2(PKD1): c.359T> C (p.Ile120Thr) single nucleotide variant Likely pathogenic GRCh37 Chromosome 16, 2169115: 2169115
7 CSMD3 GRCh37/hg19 8q23.3(chr8: 114378494-114450308) copy number loss Benign GRCh37 Chromosome 8, 114378494: 114450308

Expression for Hemangioma

Search GEO for disease gene expression data for Hemangioma.

Pathways for Hemangioma

Pathways related to Hemangioma according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 ANGPT2 FGF2 FLT4 KDR KRAS PTEN
2
Show member pathways
13.22 ANGPT2 FGF2 FLT4 KDR KRAS PTEN
3
Show member pathways
12.85 ANGPT2 FGF2 FLT4 KDR KRAS PTEN
4
Show member pathways
12.83 FLT4 KDR KRAS PTEN VEGFA
5 12.72 FGF2 FLT4 KRAS PTEN SLC2A1 VEGFA
6
Show member pathways
12.7 FGF2 KDR KRAS PTEN VEGFA
7 12.64 ANGPT2 FGF2 FLT4 KDR KRAS TEK
8
Show member pathways
12.43 FLT4 KDR KRAS PTEN
9
Show member pathways
12.41 KRAS SLC2A1 VEGFA VHL
10
Show member pathways
12.4 ANGPT2 FGF2 FLT4 KDR KRAS KRIT1
11
Show member pathways
12.33 FGF2 FLT4 KDR VEGFA
12
Show member pathways
12.33 FGF2 FLT4 KDR KRAS TEK
13 12.23 FGF2 KDR KRAS VEGFA
14
Show member pathways
12.15 FGF2 KDR KRAS PTEN VEGFA
15
Show member pathways
12.14 FLT4 KDR KRAS PTEN TEK
16 12.06 FLT4 KDR KRAS PTEN TEK
17 12.05 ANGPT2 FGF2 FLT4 KDR TEK
18
Show member pathways
12.01 ANGPT2 FGF2 FLT4 KDR KRAS
19 11.99 FGF2 KDR PROX1 VEGFA
20
Show member pathways
11.8 FLT4 KDR VEGFA VHL
21
Show member pathways
11.74 FLT4 KDR KRAS
22 11.72 FGF2 SLC2A1 VEGFA
23 11.72 ANGPT2 SLC2A1 TEK VEGFA VHL
24 11.62 KRAS PTEN SLC2A1
25 11.53 SLC2A1 VEGFA VHL
26 11.51 ACTC1 FGF2 KDR
27 11.47 FGF2 KDR VEGFA
28 11.43 FGF2 KDR VEGFA
29 11.32 ANGPT2 SLC2A1 VEGFA
30 11.2 KDR SLC2A1 VEGFA VHL
31 11.12 ANGPT2 FGF2 FLT4 KDR PDPN PROX1
32 11.03 FGF2 FLT4 KDR VEGFA
33 10.98 FGF2 FLT4 KDR KRAS VEGFA
34 10.96 ANGPT2 FGF2 FLT4 KDR TEK
35 10.94 FGF2 KDR TEK VEGFA
36
Show member pathways
10.9 FLT4 KDR VEGFA

GO Terms for Hemangioma

Cellular components related to Hemangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 ANGPT2 CD34 FGF2 FLT4 KDR PTEN
2 apical plasma membrane GO:0016324 9.35 CD34 PDPN PTEN SLC2A1 TEK
3 membrane raft GO:0045121 9.02 KDR KRAS PDPN SLC2A1 TEK
4 cytoplasm GO:0005737 10.03 ACTC1 CCM2 CD34 FLT4 KDR KRAS

Biological processes related to Hemangioma according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.98 CD34 KDR VEGFA VHL
2 positive regulation of cell proliferation GO:0008284 9.98 FGF2 FLT4 KDR KRAS PROX1 PTEN
3 peptidyl-tyrosine phosphorylation GO:0018108 9.92 FGF2 FLT4 KDR TEK
4 response to hypoxia GO:0001666 9.92 ANGPT2 SLC2A1 TEK VEGFA
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 FGF2 FLT4 KDR PTEN TEK
6 negative regulation of apoptotic process GO:0043066 9.92 ACTC1 FLT4 KDR PDPN PTEN TEK
7 positive regulation of gene expression GO:0010628 9.91 ACTC1 CD34 KRAS NKX2-1 PTEN RPL5
8 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.86 FLT4 KDR TEK
9 positive regulation of protein phosphorylation GO:0001934 9.85 FLT4 KDR KRAS TEK VEGFA
10 positive regulation of MAP kinase activity GO:0043406 9.83 FGF2 KRAS VEGFA
11 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.83 FLT4 KDR VEGFA
12 vasculogenesis GO:0001570 9.82 CCM2 KDR VEGFA
13 lung development GO:0030324 9.81 NKX2-1 PDPN PROX1 VEGFA
14 positive regulation of blood vessel endothelial cell migration GO:0043536 9.79 FGF2 KDR VEGFA
15 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.76 FGF2 KDR VEGFA
16 negative regulation of endothelial cell apoptotic process GO:2000352 9.75 KDR KRIT1 TEK
17 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.73 FLT4 KDR VEGFA
18 positive regulation of angiogenesis GO:0045766 9.73 ANGPT2 CD34 FGF2 KDR TEK VEGFA
19 sprouting angiogenesis GO:0002040 9.72 FLT4 TEK VEGFA
20 positive regulation of focal adhesion assembly GO:0051894 9.71 KDR TEK VEGFA
21 regulation of synaptic transmission, GABAergic GO:0032228 9.68 KRAS PTEN
22 skeletal muscle thin filament assembly GO:0030240 9.68 ACTC1 PROX1
23 lymph vessel development GO:0001945 9.68 FLT4 PROX1
24 positive regulation of positive chemotaxis GO:0050927 9.67 KDR VEGFA
25 positive regulation of cellular component movement GO:0051272 9.67 PDPN VEGFA
26 positive regulation of vasculogenesis GO:2001214 9.67 CD34 KDR
27 cell migration involved in sprouting angiogenesis GO:0002042 9.67 FGF2 KDR VEGFA
28 stem cell proliferation GO:0072089 9.66 CD34 FGF2
29 positive regulation of protein kinase C signaling GO:0090037 9.66 FLT4 VEGFA
30 vascular endothelial growth factor signaling pathway GO:0038084 9.65 FLT4 KDR VEGFA
31 paracrine signaling GO:0038001 9.64 CD34 FGF2
32 venous blood vessel morphogenesis GO:0048845 9.63 CCM2 PROX1
33 endothelium development GO:0003158 9.63 CD34 KDR
34 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.61 KDR VEGFA
35 actin-mediated cell contraction GO:0070252 9.6 ACTC1 PDPN
36 glomerulus vasculature development GO:0072012 9.59 ANGPT2 TEK
37 lymphangiogenesis GO:0001946 9.58 FLT4 PDPN PROX1
38 Tie signaling pathway GO:0048014 9.57 ANGPT2 TEK
39 positive regulation of endothelial cell migration GO:0010595 9.55 FLT4 KDR PROX1 TEK VEGFA
40 positive regulation of endothelial cell proliferation GO:0001938 9.43 FGF2 FLT4 KDR PROX1 TEK VEGFA
41 angiogenesis GO:0001525 9.23 ANGPT2 FGF2 FLT4 KDR KRIT1 PTEN
42 multicellular organism development GO:0007275 10.19 ANGPT2 CCM2 FGF2 KDR PDPN PROX1
43 cell differentiation GO:0030154 10.17 ANGPT2 FGF2 FLT4 KDR TEK VEGFA

Molecular functions related to Hemangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.67 ANTXR1 FLT4 KDR TEK
2 platelet-derived growth factor receptor binding GO:0005161 9.4 PTEN VEGFA
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 FLT4 KDR TEK
4 vascular endothelial growth factor-activated receptor activity GO:0005021 9.26 FLT4 KDR
5 protein tyrosine kinase activity GO:0004713 9.26 FGF2 FLT4 KDR TEK
6 growth factor binding GO:0019838 8.8 FLT4 KDR TEK
7 protein binding GO:0005515 10.25 ANGPT2 ANTXR1 CCM2 FGF2 FLT4 KDR

Sources for Hemangioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....